Gamida Cell Ltd (GMDA) Stock Forecast & Analysis
Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Gamida Cell Ltd (GMDA:NASDAQ), powered by AI.
- Current Price
- $0.03
- Sector
- Healthcare
What is the Gamida Cell Ltd stock price forecast?
Gamida Cell Ltd is currently trading at $0.03. View real-time AI analysis on Alpha Lenz.
What is Gamida Cell Ltd insider trading activity?
View the latest insider trading data for Gamida Cell Ltd on Alpha Lenz.
What is Gamida Cell Ltd's P/E ratio?
View Gamida Cell Ltd's valuation metrics on Alpha Lenz.
Gamida Cell Ltd
NASDAQ · GMDA“Gamida Cell Ltd's ROE is 1148.3%. Explore profitability and growth together.”
Ask for details →Company Overview
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.
Company Statistics
FY 2023Profile
Margins
Valuation
Growth (CAGR)
Returns
Financial Health
“Gamida Cell Ltd's ROE is 1148.3%. Explore profitability and growth together.”
Ask for details →Frequently Asked Questions
Gamida Cell Ltd (ticker: GMDA) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 143 employees.
The current price is $0.033 with a P/E ratio of -x and P/B of -x.
ROE is 1148.30% and operating margin is -4071.92%. Annual revenue is $2M.